Oral ensartinib is effective in patients with co-existing ALK fusion and point mutations
oleh: Zhijian Yao, Xin Li, Xiyu An, Dongyu Cui
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2023-09-01 |
Deskripsi
No description available for this item.
oleh: Zhijian Yao, Xin Li, Xiyu An, Dongyu Cui
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2023-09-01 |
No description available for this item.